Feb 11, 2021 7:15am EST Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
Jan 15, 2021 6:30am EST Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
Jan 12, 2021 7:00am EST Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
Dec 22, 2020 6:30am EST Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
Dec 07, 2020 6:45am EST Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences
Dec 01, 2020 6:30am EST Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs
